These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35037076)

  • 1. Diagnostic performance of fusion (US/MRI guided) prostate biopsy: propensity score matched comparison of elastic versus rigid fusion system.
    Ferriero M; Tuderti G; Muto GL; Fiori C; Bove AM; Mastroianni R; Anceschi U; Misuraca L; Brassetti A; De Cillis S; Checcucci E; Guaglianone S; Gallucci M; Porpiglia F; Simone G
    World J Urol; 2022 Apr; 40(4):991-996. PubMed ID: 35037076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software-based systems.
    Hanske J; Risse Y; Roghmann F; Pucheril D; Berg S; Tully KH; von Landenberg N; Wald J; Noldus J; Brock M
    Prostate; 2022 Feb; 82(2):227-234. PubMed ID: 34734428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsy.
    Oderda M; Albisinni S; Benamran D; Calleris G; Ciccariello M; Dematteis A; Diamand R; Descotes JL; Fiard G; Forte V; Giacobbe A; Marquis A; Marra G; Messas A; Muto G; Peltier A; Rius L; Simone G; Roumeguere T; Faletti R; Gontero P
    Prostate; 2023 Feb; 83(2):162-168. PubMed ID: 36259316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fusion US/MRI prostate biopsy using a computer aided diagnostic (CAD) system.
    Ferriero M; Anceschi U; Bove AM; Bertini L; Flammia RS; Zeccolini G; DE Concilio B; Tuderti G; Mastroianni R; Misuraca L; Brassetti A; Guaglianone S; Gallucci M; Celia A; Simone G
    Minerva Urol Nephrol; 2021 Oct; 73(5):616-624. PubMed ID: 33179868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomized controlled trial comparing target prostate biopsy alone approach vs. target plus standard in naïve patients with positive mpMRI.
    Porpiglia F; Checcucci E; DE Cillis S; Piramide F; Amparore D; Piana A; Volpi G; Granato S; Zamengo D; Stura I; Alladio E; Migliaretti G; DE Luca S; Bollito E; Gned D; DI Dio M; Autorino R; Manfredi M; Fiori C
    Minerva Urol Nephrol; 2023 Feb; 75(1):31-41. PubMed ID: 36626117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
    Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
    J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
    Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
    Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
    Lim CS; Abreu-Gomez J; Carrion I; Schieda N
    AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictors of Prostate Cancer at Fusion Biopsy: The Role of Positive Family History, Hypertension, Diabetes, and Body Mass Index.
    Oderda M; Dematteis A; Calleris G; Conti A; D'Agate D; Falcone M; Marquis A; Montefusco G; Marra G; Gontero P
    Curr Oncol; 2023 May; 30(5):4957-4965. PubMed ID: 37232832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
    Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
    Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.
    Tewes S; Hueper K; Hartung D; Imkamp F; Herrmann TR; Weidemann J; Renckly S; Kuczyk MA; Wacker F; Peters I
    World J Urol; 2015 Nov; 33(11):1707-14. PubMed ID: 25774003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
    Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
    AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
    Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
    Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of magnetic resonance imaging fusion-targeted biopsy of prostate imaging reporting and data system 3 lesions.
    Kim TJ; Lee MS; Hwang SI; Lee HJ; Hong SK
    World J Urol; 2019 Aug; 37(8):1581-1586. PubMed ID: 30460594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
    Hermie I; Van Besien J; De Visschere P; Lumen N; Decaestecker K
    Eur J Radiol; 2019 May; 114():92-98. PubMed ID: 31005183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; Gandaglia G; Fossati N; Brembilla G; Cristel G; Dehò F; Scattoni V; Maga T; Losa A; Gaboardi F; Cardone G; Esposito A; De Cobelli F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 Jun; 1(2):120-128. PubMed ID: 31100235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial experience of magnetic resonance imaging/ultrasonography fusion transperineal biopsy: Biopsy techniques and results for 75 patients.
    Tae JH; Shim JS; Jin HJ; Yoon SG; No TI; Kim JY; Kang SH; Cheon J; Kang SG
    Investig Clin Urol; 2018 Nov; 59(6):363-370. PubMed ID: 30402568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.